Over two million patients around the world suffer from End Stage Renal Disease (ESRD). Patients’ survival depends on dialysis, a renal replacement therapy that they undergo until they receive a kidney transplant. The survival rate of patients under dialysis is less than 40% in 5 years.
A year of dialysis of each patient may cost $82,000 in the United States. Patients endure a lot more hardships due to complications and lifestyle restrictions. Studies show that longer treatment times can potentially be associated with prolonged survival.
Qidni Labs is on an implantable renal replacement therapy. This device would reduce several costs associated with dialysis equipment, caregivers and insurance providers. Qidni Labs is creating an opportunity for patients to have access to renal replacement therapy continuously and at all times.